Supplementary methods, S1-S3 Figs, S1 Table.

Hafner, Michael; Paukner, Susanne; Wicha, Wolfgang W.; Hrvačić, Boška; Cedilak, Matea; Faraho, Ivan; Gelone, Steven P.

doi:10.1371/journal.pone.0237659.s001

pone.0237659.s001.pdf (517.69 kB)

Supplementary methods, S1-S3 Figs, S1 Table.

journal contribution

posted on 2021-09-29, 17:25 authored by Michael Hafner, Susanne Paukner, Wolfgang W. Wicha, Boška Hrvačić, Matea Cedilak, Ivan Faraho, Steven P. Gelone

(PDF)

History

Usage metrics

Keywords

pleuromutilin antibiotic approved measured 4h postchallenge div >< p acquired bacterial pneumonia 10 ‒ 140mg 10 ‒ 100mg mediated lung injury >, neither lefamulin several antibiotics demonstrate mouse lung tissue inflammatory mediator induction csf ), chemokine neutrophilic lung infiltration immunomodulatory activity studies 2 mouse macrophage lefamulin versus azithromycin future lefamulin anti 600mg oral ).kg subcutaneous lefamulin inflammatory activity may lung homogenates mouse airways subcutaneous azithromycin neutrophilic chemotaxis neutrophil infiltration immunomodulatory activities demonstrate inhibition 2 ),inflammatory activity kg ).chemokine levels chemokine concentrations cabp ).inflammatory cytokine vivo vitro treat community treat cabp severe inflammation results suggest relevant influence induced cytokine first study elucidate mechanism direct interaction dependently reduced dependent reductions cystic fibrosis comparators azithromycin administered 30min 9 levels 150mg intravenous

Licence

CC BY 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Supplementary methods, S1-S3 Figs, S1 Table.

History

Usage metrics

Categories

Keywords

Licence

Exports